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ABSTRACT
Controlling the patterns of splicing of specific genes
is an important goal in the development of new
therapies. We have shown that the splicing of a re-
fractory exon, SMN2 exon 7, could be increased in
fibroblasts derived from patients with spinal
muscular atrophy by using bifunctional targeted
oligonucleotide enhancers of splicing (TOES) oligo-
nucleotides that anneal to the exon and contain a
‘tail’ of enhancer sequences that recruit activating
proteins. We show here that there are striking
agreements between the effects of oligonucleotides
on splicing in vitro and on both splicing and SMN2
protein expression in patient-derived fibroblasts,
indicating that the effects on splicing are the major
determinant of success. Increased exon inclusion
depends on the number, sequence and chemistry
of the motifs that bind the activator protein SRSF1,
but it is not improved by increasing the strength of
annealing to the target site. The optimal oligo-
nucleotide increases protein levels in transfected
fibroblasts by a mean value of 2.6-fold (maximum
4.6-fold), and after two rounds of transfection
the effect lasted for a month. Oligonucleotides
targeted to the upstream exon (exon 6 in SMN) are
also effective. We conclude that TOES oligonucleo-
tides are highly effective reagents for restoring the
splicing of refractory exons and can act across long
introns.
INTRODUCTION
Pre-mRNA splicing is becoming a major target for the
development of therapies. This situation has arisen for
two reasons. First, it is evident that alternative splicing
makes a major contribution to the regulation of gene ex-
pression. Almost all, 94%, of protein-coding genes
contain introns and of these 90% show signiﬁcant levels
of alternative splicing; around 70% of these splices are
tissue speciﬁc (1). Thus, a high proportion of mRNA se-
quences and proteins arise by alternative splicing and con-
tribute to development. The second important factor is
that the choice of splice sites depends on a number of
very subtle aspects of the pre-mRNA sequence. These
not only affect the use of bona ﬁde sites but they are
also required to distinguish between real sites and the
very large number of sequences resembling splice sites
that can be found in most genes (2,3). Indeed, it is
estimated that between 12 and 19 distinct cues are
involved in the selection of tissue-speciﬁc splice sites (4).
The existence of alternative sites, the abundance of similar
sequences and the activation or suppression of alternative
sites in speciﬁc tissues all contribute to a system that
appears to be vulnerable to mutations or to changes in
the concentrations of the proteins that recognize these se-
quences. It is unsurprising that genetic diseases are
commonly found to arise from mutations in se-
quences that affect splicing or that the progression of
acquired diseases involves substantial changes in splicing
patterns (5).
The ﬁrst strategy used to redirect splicing for
therapeutic purposes involved the use of oligonucleo-
tides complementary to splice sites or, more recently,
enhancer sequences (6–9). These were intended to
block the binding of essential splicing factors at a
speciﬁc exon, causing it to be skipped. This strategy
has been proved to be very effective, and promising
results have emerged from clinical trials of oligo-
nucleotides that promote the skipping of a mutant dys-
trophin exon that causes Duchenne muscular dystrophy
(10,11).
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inclusion of an exon. This is important for restitution of
survival of motor neuron (SMN) protein expression in
spinal muscular atrophy (SMA). SMA is a common auto-
somal recessive disorder caused by mutations in the gene
SMN1. It is characterized by degeneration of the motor
neurons in the anterior horn of the spinal cord, resulting
in muscular atrophy and weakness, but the severity of the
phenotype is modiﬁed by the copy number of a second
SMN gene, SMN2, which is present as a result of an
inverted duplication in chromosome 5q13. The SMN
genes have eight exons, the ﬁrst seven of which encode a
294 amino acid protein, but in SMN2 the majority of
mRNA products lack exon 7 and the levels of functional
full-length protein derived from SMN2 are very low as a
result (12).
Two strategies have emerged for stimulating the inclu-
sion of exon 7: the use of oligonucleotides that block
silencer motifs or the use of bifunctional oligonucleotides.
It is still difﬁcult to predict the location of enhancer
and silencer motifs within an exon (2,3), and the most
effective route for ﬁnding appropriate oligonucleotides
that block silencers is either to perform a systematic
screen with a large number of candidate oligonucleotides
(13,14) or to map the silencers by experiment. The other
strategy is to increase the number of positively acting
signals in an exon, which led us to invent bifunctional
oligonucleotides (15). The oligonucleotides were de-
signed with one domain that was intended to anneal
to the target exon and a second (tail) domain that con-
tained sequences to which activator proteins, such as the
SR proteins, would bind (Figure 1). We demonstrated
that one such oligonucleotide stimulated the splicing
of SMN2 exon 7 in a model pre-mRNA in nuclear
extracts and that it stimulated both splicing and SMN
protein expression in ﬁbroblasts derived from SMA
patients. We designated this method as targeted oligo-
nucleotide enhancers of splicing (TOES) (16). At the
same time, peptide–PNA compounds were developed for
the same purpose; in these, the PNA sequence annealed to
the target exon and the peptide comprised repeats of an
arginine–serine dipeptide that mimicked the activation
(RS) domains of SR proteins. These are also effective in
rescuing the splicing of a refractory exon in nuclear
extracts (17).
The effectiveness of TOES as a potential therapy for
SMA has been tested subsequently by two different
strategies. A bifunctional oligonucleotide targeted to
SMN2 exon 7 has been expressed in transgenic mice
within a modiﬁed U7 snRNA gene. Expression of the
TOES-U7 RNA in a mouse model of SMA produced a
very substantial improvement in function and lifespan
(18). Another variation of TOES involved targeting an
intronic silencer upstream of SMN2 exon 7; this
appeared to have the dual effect of blocking the silencer
and recruiting activator proteins (19). Interestingly, this
strategy resulted in increased inclusion of exon 7 when
the oligonucleotides were injected into intracerebral ven-
tricles, even though the recruitment of SR proteins to a
site in an intron has been shown in other cases to inhibit
splicing (20).
Optimizing the design of a TOES oligonucleotide
requires consideration of a number of variables beyond
those normally associated with a complementary silencing
oligonucleotide. Obviously the sequence of the
non-complementary tail has to represent an optimal
binding site for an activator protein, but other factors
include the best choice of protein, the number of protein
molecules that need to be bound for maximum effective-
ness, the ability of the protein to bind stable analogues of
RNA and the optimal locations of the proteins relative to
their sites of action.
Figure 1. Design of TOES. The sequence of the SMN genes around exon 7 is shown, with the sequence of exon 7 in upper case and ﬂanking intron
sequences in lower case. Nucleotide 6 is shown as an asterisk, being C in SMN1 and T in SMN2. The shaded sequence is an enhancer that is
recognized by Tra2b. Oligonucleotide 1 is shown annealed to nucleotides 2–16. The tail and annealing domains, shown in different colours, and the
50-end of the tail (cap) may contain different nucleotide analogues in the oligonucleotides being tested. The line diagrams below the exon show
oligonucleotides that anneal to different sites, the sites being shown by the nucleotide positions in the exon; the oligonucleotides are numbered as in
Table 1.
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could be identiﬁed reliably it might be thought best not to
obstruct them, although a TOES oligonucleotide might
have a dominant positive effect anyway. A second
problem is that it is difﬁcult to judge where an enhancer
should be tethered because too little is known at a mo-
lecular level about where and how enhancer-bound SR
proteins exert their effects. Following the identiﬁcation
of SR proteins as the main mediators of the effects of
enhancer sequences (21), and evidence that they could
mediate protein interactions via their RS domains (22),
two very important mechanistic insights were made:
(i) we showed that SR protein SRSF1 strengthened the
binding of U1 snRNP complexes at 50-splice sites (23),
even though, as with the effects of SRFS1 on the selection
of alternative 50-splice sites (24,25), its RS domain is not
required (26), and (ii) others showed that SR proteins
enhanced the binding of the protein U2AF at upstream
30-splice sites (27,28). These and subsequent observations
led to the common picture that SR proteins bound to an
exon stabilize complex formation at the ﬂanking splice
sites and thereby increase the probability of splicing to
that exon, although the nature and number of the inter-
actions involved is not known. However, recent investiga-
tions suggest that SR proteins bound to an exon stabilize
RNA:RNA base pairing of U2 snRNA at the branchpoint
and U6 snRNA at the 50-splice site at later stages in
spliceosome assembly (29,30). Thus, it is not yet clear
which interactions should be targeted when designing a
TOES oligonucleotide. We describe here an investigation
into constraints on the design of the oligonucleotide, and
suggest that this design has to reﬂect the rate-limiting steps
in splicing to an exon. We have applied this to SMA as a
model system and describe a highly effective TOES
reagent inducing SMN2 exon 7 inclusion.
MATERIALS AND METHODS
Oligonucleotides
Oligonucleotides were synthesized and puriﬁed by
Eurogentec. They were dissolved to standard concentra-
tions and stored according to the manufacturer’s
instructions.
Splicing in vitro
Radiolabelled transcripts were prepared as described pre-
viously from a construct comprising SMN2 exon 7 and
ﬂanking intron sequences ( 150nt from intron 6 and
300 from intron 7) inserted into a shortened version of
rabbit b-globin intron 2 and ﬂanking exon sequences
(15). A mixture of oligonucleotide and transcript was
heated at 70 C for 30s and then allowed to cool to
ambient temperature over 30min. A mixture of nuclear
extract, buffer, salts and ATP was added, producing
ﬁnal concentrations of 2mM MgCl2, 38.5mM KCl,
2mM ATP, 10mM creatine phosphate and 35% nuclear
extract (Cilbiotech). Reactions were incubated at 30 C for
2h. After treatment, samples were analysed on 6%
denaturing polyacrylamide gels. The radiation present in
the two isoforms of mRNA and the remaining pre-mRNA
was quantiﬁed with a phosphor imager (Packard),
adjusted for the content of radiolabelled nucleotides and
the proportion of exon inclusion mRNA calculated. This
ﬁgure was expressed as a ratio relative to the level of in-
clusion of RNA spliced in parallel in the absence of oligo-
nucleotides. Splicing assays to test the effect of the
mutation in the ESE (Figure 7) were done in 50%
nuclear extract, 3.2mM MgCl2, 50mM KCl, 50mM K
glutamate. For ribonuclease H cleavage assays, the
TOES oligonucleotides were annealed to pre-mRNA in
100mM K glutamate, 50mM Hepes.KOH, and then
incubated in 40% nuclear extract as for splicing but in
the absence of ATP and creatine phosphate. After 5min
at 30 C, the DNA oligonucleotide was added to 500nM
and ribonuclease H to 0.5U/ml, and incubation was
continued for 30min.
Transfection of SMA ﬁbroblasts
Skin ﬁbroblast cell line 7384 was derived from a patient
with type II SMA who has a homozygous deletion of the
SMN1 gene and three copies of SMN2. Fibroblasts were
cultured in DMEM containing 10% foetal calf serum.
Cells were seeded into six-well plates with a concentration
of  2 10
5 cells per well, which gives 90% conﬂuence
when transfected the next day. Oligonucleotides were
complexed with Lipofectamine 2000 (Invitrogen) in
Opti-MEM (Invitrogen) according to the manufacturer’s
instructions, and added to the cells. Cells were harvested
12h post-transfection for RNA extraction, and 24h
post-transfection for protein extraction. All transfections
have been repeated at least three times throughout the
entire study.
Reverse transcription PCR and quantitative
real-time PCR
Total RNA from the cultured cells was extracted with the
Qiagen RNeasy kit. Almost 500ng of each RNA sample
was used for ﬁrst-strand cDNA synthesis with a
Superscript III reverse transcription kit (Invitrogen).
Primers (Forward: 50- CTC CCA TAT GTC CAG ATT
CTC TT-30 and Reverse: 50-CTA CAA CAC CCT TCT
CAC AG-30) were used to amplify full-length (505bp) and
D7 SMN2 (451bp) from cDNA. The products were
ampliﬁed semi-quantitatively using 25 PCR cycles (94 C
for 30s, 55 C for 30s and 72 C for 30s). All PCR
products were checked by running on 1% agarose gels.
Quantitative real-time PCR was done with the
Eurogentec MESA Blue qPCR kit. Samples were
incubated in a 25ml reaction mix according to manufac-
turer’s instructions. The same cDNA products as above
were used as template for real-time PCR. The speciﬁc
full-length SMN2 primers, forward 50-ATA CTG GCT
ATT ATA TGG GTT TT-30 and reverse 50-TCC AGA
TCT GTC TGA TCG TTT C-30 (133bp); and speciﬁc
SMN D7 primers, forward 50-TGG ACC ACC AAT
AAT TCC CC-30 and reverse 50-ATG CCA GCA TTT
CCA TAT AAT AGC C-30 (125bp) were used.
Quantitative real-time PCR was performed using
Applied Biosystem fast 7500 Real Time PCR System
using the recommended programme: activation at 95 C
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Quantiﬁcation was based on concurrent standard curves
produced from serial dilutions of cDNA from untreated
7384 SMA ﬁbroblasts. The cycle at which the amount of
ﬂuorescence was above the threshold (Ct) was detected.
The ratios of full-length SMN2 to 7 SMN2 of the
treated samples were normalized taking the ratio of the
untreated sample as 1.0.
Western blotting
Fibroblasts were lysed in buffer containing 75mM Tris–
HCl (pH 6.8) and 0.25% SDS supplemented with protease
inhibitor cocktail (Roche Diagnostics). The lysates were
centrifuged at 13000g for 15min at 4 C to collect the
supernatants. The protein concentration was analysed
using a BCA kit (Pierce) according to the manufacturer’s
instructions and 5mg protein was loaded into NuPAGE
pre-cast gels (10% Bis–Tris, Invitrogen). Separated
proteins were then transferred electrophoretically to nitro-
cellulose membrane (GE Healthcare). Membranes were
blocked overnight in 10% semi-skimmed milk in
PBS-0.1% Tween, then incubated for 1h at room tem-
perature with mouse anti-SMN monoclonal antibody
(1:3000, BD Transduction laboratories) and mouse
anti-b-tubulin monoclonal antibody (Clone TUB2.1,
1:5000, Sigma) in 5% Milk–PBS–Tween. Membranes
were incubated for 1h at room temperature followed
with secondary HRP-conjugated anti-mouse IgG
antibody (Amersham) at a dilution of 1:50000 in PBS–
Tween. Blots were developed using an enhanced chemilu-
minescence detection kit (GE Healthcare). Quantiﬁcation
was done with ImageJ software.
Protein–RNA interactions
To assay the binding of recombinant SRSF1 by native gel
electrophoresis, 1.5pmol of 50-end-labelled oligonucleo-
tide 27 were incubated on ice for 15min with 20pmol
SRSF1 in 5ml of 20mM Tris–HCl, pH 7.5, 100mM
KCl, 10mM MgCl2. A 25pmol of competitor oligo-
nucleotide was added, as labelled in Figure 7, and incuba-
tion continued for an hour. Subsequently, 3ml of 80%
glycerol were added, and 5ml portions loaded on a
pre-cooled native gel (10% polyacrylamide, 25mM Tris
base, 200mM glycine, 5% glycerol). Electrophoresis was
for 1h at 4 C at 20V/cm.
For immunoprecipitation, protein G agarose bead
slurry (50%) was preincubated with mAB96 antibody
(Zymed) in PBS containing 0.1mg/ml BSA for 2h at
4 C with rotation. Antibody-bound protein G was
washed by pelleting at 12000g at 4 C in PBS.
50-end-labelled oligonucleotide (2pmol/ml) was incubated
with 10ml antibody-bead complexes, 0.8mg SRSF1 and
400ml IPP200 Buffer (20mM HEPES pH 7.9, 1.5mM
MgCl2, 0.05% NP40 and 200mM NaCl) for 2h at 4 C.
Protein-antibody bead complexes were pelleted at 12000g
and washed for 15min at 4 C in IPP200 three times. Final
pelleted samples were resuspended in 10ml2  SDS
sample buffer and separated by electrophoresis in SDS
on 15% polyacrylamide gels. Gels were dried on 3MM
Whatman paper and exposed to a phosphor screen.
RESULTS
TOES oligonucleotides contain a protein binding domain
(tail) comprising repeated motifs believed to be optimal
binding sites for speciﬁc proteins. In the ﬁrst exemplars,
the annealing domain was complementary to nucleotides
2–16 of SMN2 exon 7. Motifs that were known binding
sites for an activator, SRSF1, stimulated inclusion and
those for two inhibitors, polypyrimidine tract binding
protein (PTB) and hnRNP A1, reduced the efﬁciency of
splicing in vitro (15).
To establish principles for designing TOES oligonucleo-
tides, we varied the chemical structure of the nucleotide
analogues in the tail and the annealing domain, the
number of potential binding sites in the tail, the sequences
of these sites and the sites of annealing of the oligonucleo-
tide. The efﬁcacy of the oligonucleotides was assessed by
measuring the splicing of SMN exon 7 in nuclear extracts
and by transfection of 7384 ﬁbroblasts derived from a
SMA patient, measuring both changes in SMN2 splicing
by real time PCR and SMN protein expression.
Oligonucleotides were used at concentrations of 250,
500, 1000 and 5000nM for splicing in vitro and at 50,
100 and 250nM for the transfection of cells. Table 1 sum-
marizes the results obtained with the oligonucleotides at
250nM. It is important to note that the values stated for
splicing in vitro show the relative increase in the level of
exon inclusion mRNA as a proportion of the sum of the
unspliced pre-mRNA and the two isoforms of spliced
mRNA. The purpose of this is to avoid using the ratio
of inclusion and exclusion isoforms alone, which might
produce an apparent increase in inclusion if skipping
had been inhibited. The values stated for splicing in ﬁbro-
blasts cannot be readily presented in the same way, and
they show the ratio of inclusion mRNA to exclusion
mRNA, normalized against untreated cells. However,
these results can be compared with measurements of the
relative levels of SMN protein in treated and untreated
cells, which would allow aberrant measurements resulting
from the inhibition of skipping to be detected.
The effects of oligonucleotides on splicing in vitro and in
SMA ﬁbroblasts are compared in Figure 2. These effects
show a striking agreement for most of the oligonucleotides
that stimulate inclusion, which suggests that their different
effects on exon 7 inclusion in SMA ﬁbroblasts result from
their effects on splicing as opposed to differences in the
stability or uptake of the oligonucleotides. Moreover, an
increase in the proportion of exon 7 inclusion in vitro is
generally associated with increased levels of SMN protein
expression (Figure 3), which suggests that there are no
signiﬁcant detrimental effects of the oligonucleotide on
translation. We conclude that the efﬁciency of splicing
to exon 7 is the main determinant of the levels of SMN
protein expression after treatment with TOES
oligonucleotides.
The length of the tail domain
The original oligonucleotide (number 1 in Table 1) con-
tained six repeats of the motif GGA, within three repeats
of the sequence GGAGGAC. We tested whether it would
be possible to use oligonucleotides with shorter tails by
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motifs. Table 1 shows the oligonucleotides arranged in
blocks according to the chemistries of their three parts,
the ranking within each block being determined by the
effectiveness with which they stimulated exon 7 inclusion
in transfected ﬁbroblasts. Comparison of oligonucleotides
1, 3 and 6 shows that their effectiveness both in vitro and
in vivo depends directly upon the number of GGA repeats
(6, 5 and 3, respectively), and oligonucleotides lacking
either a tail or an annealing domain are inactive
(Figures 2 and 3; representative western blots and a quali-
tative PCR analysis of splicing from transfected cells are
shown in Figure 4A and B).
Sequence of the tail domain
The GGA motifs in oligonucleotide 1 were chosen on the
basis that they appeared to be core elements of the binding
site for the SR protein SRSF1. We tested two other
sequences that have been identiﬁed as functional binding
sites for SRSF1: oligonucleotide 7, which has two copies
of CAGACG (31) in its tail of 19nt, and oligonucleotide
17, which has a tandem repeat of CCGCGGA (32) in a
tail of 20nt. In comparison with oligonucleotides 3 and
10, which have ﬁve GGA motifs in RNA tails of 20nt with
the appropriate pS/20-O-methyl and LNA/20-O-methyl
annealing domains, respectively, both alternative tail
Table 1. Summary of properties and activities of oligonucleotides
Number Tail sequence Position Chemistry summary In vitro In vivo Protein level
Cap Tail Annealing 250nM SEM 250nM SEM 250nM SEM
1 AGGAGGACGGAGGACGGAGGACA 2–16 pS RNA pS/20OMe 1.90 0.10 7.58 0.43 2.60 0.24
2 AGGAGGACGGAGGACGGAGGACA Exon 6 pS RNA pS/20OMe 6.17 0.78 1.63 0.11
3 AGGACGGAGGACGGAGGACA 2–16 pS RNA pS/20OMe 1.78 0.15 4.93 0.10 1.72 0.13
4 AGGAGGACGGAGGACGGAGGACA 2–16 pS RNA pS 1.75 0.17 3.71 0.26 1.69 0.21
5 Exon 6 pS/20OMe 3.24 0.54 0.97 0.05
6 AGGACGGAGGACA 2–16 pS RNA pS/20OMe 1.30 0.07 2.95 0.07 1.47 0.08
7 AACCAGACGACAGACGAAA 2–16 pS RNA pS/20OMe 1.21 0.01 2.66 0.19 1.34 0.23
8 2–16 pS/20OMe 1.10 0.05 1.08 0.04 1.05 0.18
9 AGGAGGACGGAGGACGGAGGACA 2–16 LNA RNA LNA/20OMe 1.58 0.40 3.47 0.51 1.73 0.13
10 AGGACGGAGGACGGAGGACA 2–16 LNA RNA LNA/20OMe 1.55 0.09 2.85 0.08 1.48 0.15
11 GAAGAAGAAGCUAGGACGGAGGACGGAGGACA 2–16 LNA RNA LNA/20OMe 1.41 0.19 1.76 0.43 1.13 0.10
12 AGGACGGAGGACGGAGGACA 7–21 LNA RNA LNA/20OMe 1.16 0.05 1.46 0.40 1.44 0.10
13 AGGACGGAGGACGGAGGACA 2–16 RNA RNA LNA/20OMe 1.18 0.13 1.39 0.31 1.47 0.07
14 CAAGAAGAAGAAGCU 2–16 LNA RNA LNA/20OMe 1.11 0.18 1.38 0.16 1.26 0.15
15 7–21 LNA/20OMe 1.27 0.15 1.34 0.19 1.45 0.09
16 2–16 LNA/20OMe 1.11 0.08 1.10 0.13 0.91 0.30
17 AGGACCGCGGACCGCGGACA 2–16 LNA RNA LNA/20OMe 1.15 0.10 0.96 0.05 1.47 0.11
18 AGGACGGAGGACGGAGGACA 16–30 LNA RNA LNA/20OMe 0.56 0.13 0.06 0.01 0.78 0.05
19 AGGACGGAGGACGGAGGACA 32–46 LNA RNA LNA/20OMe 0.12 0.01 0.02 0.00 0.85 0.12
20 16–30 LNA/20OMe 0.29 0.05 0.01 0.00 0.70 0.08
21 AGGACGGAGGACGGAGGACA 18–32 LNA RNA LNA/20OMe 0.91 0.34 0.00 0.00 0.88 0.06
22 18–32 LNA/20OMe 0.29 0.09 0.00 0.00 0.82 0.09
23 32–46 LNA/20OMe 0.08 0.02 0.00 0.00 0.84 0.09
24 AGGAGGACGGAGGACGGAGGACA 2–16 20OMe 20OMe LNA/20OMe 1.28 0.16 2.87 0.10 1.53 0.11
25 AGGACGGAGGACGGAGGACA 7–21 20OMe 20OMe LNA/20OMe 1.32 0.13 1.64 0.30 1.35 0.09
26 AGGACGGAGGACGGAGGACA 2–16 20OMe 20OMe LNA/20OMe 1.76 0.07 1.19 0.24 1.52 0.21
27 AGGAGGACGGAGGACGGAGGACA 2–16 20OMe 20OMe 20OMe 1.41 0.19 5.84 0.56 1.53 0.11
28 AGGAGGACGGAGGACGGAGGACA 2–16 20OMe RNA 20OMe 3.87 0.71 1.94 0.37
29 AGGACGGAGGACGGAGGACA 2–16 20OMe 20OMe 20OMe 1.56 0.13 2.36 0.16 1.57 0.14
30 2–16 20OMe 1.11 0.04 1.01 0.04 0.94 0.24
31 AGGAGGACGGAGGACGGAGGACA pS RNApS 1.11 0.03 1.45 0.15 0.90 0.18
32 AGGACGGAGGACGGAGGACA 20OMe 20OMe 1.02 0.13 1.30 0.30 0.91 0.10
33 AGGAGGACGGAGGACGGAGGACA LNA RNA 0.54 0.05 1.21 0.07 0.99 0.26
34 CAAGAAGAAGAAGCU LNA RNA 1.03 0.03 1.11 0.13 0.75 0.02
35 AGGAGGACGGAGGACGGAGGACA 20OMe 20OMe 1.17 0.04 1.05 0.16 1.20 0.18
36 GAAGAAGAAGCUAGGACGGAGGACGGAGGACA LNA RNA 0.97 0.12 0.97 0.03 0.93 0.05
37 AGGACGGAGGACGGAGGACA LNA RNA 1.01 0.16 0.82 0.08 1.16 0.05
38 CGGAGGACGGAGGAC 2–16 M M M 1.24 0.41 0.47 0.00 0.70 0.04
39 (Scrambled) M M M 0.82 0.14 1.11 0.10 0.84 0.07
1.00 1.00 1.00
Number is the number assigned to each oligonucleotide; Position shows the nucleotides in the exon, numbered from the 50-end, to which the
oligonucleotide anneals; In vitro refers to splicing of RNA in nuclear extract and shows the proportion of mRNA including exon 7 as [inc/
(inc+exc+pre-mRNA)] in the presence of oligonucleotide at 250nM relative to the same ratio in the absence of oligonucleotide in the same
experiment, with the standard error of the mean shown (SEM); In vivo refers to splicing of the endogenous SMN2 gene in 7384 ﬁbroblasts
transfected with oligonucleotide at 250nM and shows the ratio of products including exon 7 to the products without, as determined by real-time
PCR, relative to the levels measured for parallel untransfected samples; protein level refers to the ratio of SMN protein to tubulin protein signals on
western blotting of extracts from 7384 ﬁbroblasts transfected with oligonucleotides at 250nM, relative to the same ratio in untransfected cells. The
chemistry is designated as: pS, phosphorothioate; 20OMe, 20-O-methyl; LNA, locked nucleic acid; M, morpholino. In all cases, the reference value in
the absence of oligonucleotide is taken as 1.00 (green shading).
7198 Nucleic Acids Research, 2011,Vol.39, No. 16Figure 3. Comparison of the activities of bifunctional oligonucleotides on SMN protein expression and splicing in transfected SMA ﬁbroblasts. The
level of SMN protein expression relative to that of tubulin, and expressed relative to the corresponding level in untransfected cells, is plotted against
the ratios of the mRNA isoforms determined by real-time PCR. As in Figure 3, the results are derived from experiments with the oligonucleotides at
250nM, and they are grouped according to the chemistries of the oligonucleotides used. The results for oligonucleotides 6, 3 and 1 (left to right) have
been circled.
Figure 2. Comparison of the activities of bifunctional oligonucleotides on splicing in transfected SMA ﬁbroblasts and in vitro. The ratio of inclusion
to exclusion isoforms from ﬁbroblasts transfected with oligonucleotides at 250nM, determined by quantitative real-time PCR, is plotted against the
relative increase in efﬁciency of splicing to exon 7 in vitro in the presence of oligonucleotides at the same concentration (values from Table 1). The
results have been grouped according to the chemistries of the oligonucleotides used. The results for oligonucleotides 6, 3 and 1 (left to right) have
been circled.
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in vitro and in vivo (Table 1 and Figure 4C). An important
natural enhancer sequence in the middle of exon 7
contains two GAA motifs (33), and there is evidence
that they form the binding site for the activator protein
Tra2b (34). We tested three GAA motifs in oligonucleo-
tide 14. Although this performed better than oligonucleo-
tide 17, it fell far short of oligonucleotide 10 (Table 1 and
Figure 4C). For their length and in a given chemical back-
ground, it appears that the GGA-based motifs are most
potent.
Chemistry of the tail domain
The sugars in the tail of oligonucleotide 1 are all ribose
groups. These were used because it was not clear whether
RNA binding proteins would tolerate alterations to the
ribose groups, despite the likelihood that an RNA
moiety would compromise the stability of the oligonucleo-
tide in a cell. A comparison of oligonucleotide 1 with
oligonucleotide 27, which is fully 20-O-methyl substituted
and signiﬁcantly less efﬁcient in all assays (Table 1), sug-
gested that RNA binding might be compromised.
However, oligonucleotides differing only in their tail and
cap chemistries did not show consistent differences (oligo-
nucleotides 10 and 13 versus 26 and 27 versus 28; Table 1
and Figure 5A). We infer that 20-O-methyl tails do not
impede recognition of the tail’s enhancer sequences by
activator proteins, and that the difference in performance
between oligonucleotides 1 and 27 might be attributed to
the properties of the annealing region.
Chemistry of the annealing domain
The original annealing domain was completely
substituted with 20-O-methyl groups and partially with
phosphorothioate. The principal determinants of a suc-
cessful annealing domain were expected to be the stability
of the duplex formed, the speciﬁcity of duplex formation
and the resistance of the analogue to nucleases. Since the
annealing site is rich in (A+U), it would be predicted that
increasing the stability of the hybrid by incorporating
LNA derivatives (35) into the annealing region would
increase activity.
The results in Table 1 and examples in Figure 5A show
that this expectation was not borne out, even for splicing
in vitro. Oligonucleotides 10, 13, 26 and 29, which have
tails containing 5 GGA motifs but annealing regions
comprising LNA/20-O-methyl or 20-O-methyl modiﬁca-
tions, are all less active overall than oligonucleotide 3,
which has a 20-O-methyl/phosphorothioate annealing
region; similarly, oligonucleotide 9 is less active than
oligonucleotide 1. The band in between the mRNA
isoforms that is induced by addition of the most active
oligonucleotides (1 and 3) was shown by ribonuclease H
cleavage to comprise intron 2 (Figure 5B).
Since the LNA/20-O-methyl oligonucleotides stimulated
inclusion in vitro, rather than skipping or even a failure to
splice, we can exclude any generic inhibition of splicing by
off-target annealing as a plausible explanation of their
relatively poor effects. An alternative explanation might
be that the LNA/20-O-methyl domain formed stable sec-
ondary structures that would prevent the oligonucleotide
annealing to pre-mRNA. We tested whether the oligo-
nucleotide had annealed in nuclear extracts using
ribonuclease H protection (Figure 5C). The LNA/20-O-
methyl oligonucleotide provided complete protection at
all concentrations tested. We have shown previously that
the annealing of a DNA oligonucleotide and ribonuclease
H cleavage can be treated as an irreversible pseudo-ﬁrst
order reaction such that the extent of cleavage depends on
the level of binding or rate of dissociation by other com-
ponents such as the TOES oligonucleotide (26). The
results suggest that increased stability of the duplex with
the target improves binding but reduces TOES activity.
Position of annealing
The extrinsic enhancer activity of the TOES oligonucleo-
tides may depend on the location of the tail within the
exon, and it is possible that a sequence that acts as an
enhancer in one position might act as a silencer in
another. We compared the effects of location for oligo-
nucleotides with LNA/20-O-methyl annealing domains of
A
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Figure 4. Importance of the length and sequence of the tail domain.
(A) Western blots showing SMN and tubulin proteins after transfection
of SMA ﬁbroblasts with oligonucleotides containing different lengths of
tail, as labelled above the lanes (oligonucleotide 1, 6 GGA motifs;
oligonucleotide 3, 5 GGA motifs; oligonucleotide 6, 3 GGA motifs).
The ﬁgures below the lanes show the normalized ratios of
SMN:tubulin. (B) Qualitative PCR of the spliced isoforms of endogen-
ous SMN2 mRNA after transfection of SMA ﬁbroblasts by the
designated oligonucleotides. The site annealed refers to the 50-most nu-
cleotide in the exon to which the oligonucleotide is complementary.
(C) Qualitative PCR illustrating the effectiveness of different tail
sequences.
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(Figure 6A). The results are shown in Table 1 and illus-
trative in vitro splicing and qualitative PCR reactions are
shown in Figure 6B and C. The activities of the oligo-
nucleotides decreased as the 50-end of the annealing
portion shifted from position +2 in the exon to +7, +18
and +32. Interestingly, the equivalent untailed oligo-
nucleotides at positions +7 to +32 produced similar
outcomes, so that at position +7 the oligonucleotide
stimulated splicing slightly while at position +32 it in-
hibited completely. This means that the tail contributed
signiﬁcantly only for oligonucleotides beginning at
nucleotide +2. To test whether this success depended on
the site of annealing or the tail itself, we tested another
oligonucleotide that annealed to positions 16–30 but was
fused to the tail at its 30-end. This oligonucleotide, number
18, also inhibited inclusion of exon 7 and comparison with
oligonucleotide 20 shows that the tail had little effect
(Figure 6 and Table 1). We conclude that the site of an-
nealing has a major effect on activity, as might be
expected, but that the tail only modulates this signiﬁcantly
with the oligonucleotides in which the tail is attached at
position 16 and the annealing domain is on its 30 side, i.e.
to the upstream side of the exon.
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Figure 5. Importance of nucleotide modiﬁcations in the annealing domain and their effects on the stability of the duplex. (A) Analysis of splicing
in vitro. Transcripts containing SMN2 exon 7 and ﬂanking b-globin exons were incubated with oligonucleotides, as designated by the numbers above
the lanes, and incubated in HeLa nuclear extract before analysis by polyacrylamide gel electrophoresis. The concentrations of the oligonucleotides
used were 250 or 500nM, as shown. The spliced mRNA isoforms with inclusion or exclusion of exon 7 are shown alongside the image. Splicing
intermediates are as illustrated previously (15). (B) Identiﬁcation of the bands between the mRNA isoforms. Splicing reactions were done as above in
the presence (+) or absence ( ) of oligonucleotide 1 and then incubated with ribonuclease H and DNA oligonucleotides complementary to the exon
or intron marked. (C) Pre-mRNA was incubated with oligonucleotides 1, 27 and 9, which contain the same sequence but with pS/20-O-methyl, 20-O-
methyl and LNA/20-O-methyl annealing domains, respectively, and then incubated in nuclear extract under conditions promoting formation of
committed splicing complexes ( ATP). DNA oligonucleotides with the same sequence as the annealing domain and ribonuclease H were added to
produce cleavage of any exposed pre-mRNA.
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to rescue the inhibition caused by the corresponding an-
nealing domains (oligonucleotides 20 and 22) might be
caused by the inability of the tail to recruit proteins that
compensate for the functions of proteins that would
normally bind to this part of the exon. These oligonucleo-
tides overlap the core Tra2b-dependent enhancer
(Figure 1). We tested whether the tail could compensate
for defective binding of Tra2b by mutating the binding site
from AGAAGGAAGG to CGCACGATTA, which
reduced splicing to exon 7 substantially; the 50-end of
the exon was mutated to match SMN1 to ensure a
minimal level of inclusion. Splicing in vitro (Figure 7)
showed that oligonucleotide 1 restored splicing efﬁciently,
whereas an oligonucleotide containing GAA motifs
(number 14) was ineffectual and one containing both
GGA and GAA motifs (number 11) was marginally
active. This result conﬁrms that the failure of oligonucleo-
tides 18 and 21 is not the result of a failure by the tail to
compensate for the loss of Tra2b activity but is consistent
with the possibility that the tail is inactive at positions 30
and 32.
Stimulation of splicing by bifunctional oligonucleotides
targeted to an upstream exon
We observed previously that oligonucleotide 1 appeared
to stimulate splicing in vitro of the downstream intron
preferentially. This effect can be seen also in the in vitro
splicing reactions in Figures 5A, 6B and 7, where predom-
inance of the exon 7 inclusion mRNA is associated with
increased levels of the intermediate RNA in which the
downstream intron had spliced but the upstream one
was retained. If TOES oligonucleotides have a polar
effect, acting primarily on the downstream intron, then
splicing of the upstream intron might be facilitated by a
TOES oligonucleotide that annealed to the upstream
exon. An oligonucleotide was tested that annealed to
b-globin exon 2, which is the upstream exon in our
in vitro substrate. This oligonucleotide contains ﬁve
GGA motifs in an RNA tail with an LNA cap and an
LNA/20-O-methyl annealing domain. This proved to be
effective at 250nM; at 500nM it was the most effective
oligonucleotide (bGt, Figure 6B). This principle was tested
on the endogenous SMN2 gene with an oligonucleotide
similar to oligonucleotide 1 but complementary to exon
6. Even though this oligonucleotide annealed  5800nt
upstream of exon 7, it stimulated inclusion of exon 7
very substantially (oligonucleotide 2, Table 1).
Binding of the tail to SRSF1
If bifunctional oligonucleotides act by recruiting enhancer
binding proteins such as SRSF1, then the activity of the
tail should depend on SRSF1 binding. The formation of
complexes between the oligonucleotides and recombinant
SRSFS1 was measured by a competition assay:
phosphorylated protein was incubated with labelled oligo-
nucleotide 27 (six GGA motifs, fully 20-O-
methyl-substituted) and the complexes challenged with
excess competitor oligonucleotides. After electrophoresis
on a native gel, a successful competitor will be seen to
have displaced the labelled oligonucleotide from the
complex. Figure 8A shows that a 17-fold excess of oligo-
nucleotides with six GGA motifs in the tail successfully
displaced the labelled oligonucleotide. The thin bands
above the complex and in the middle of the gel are
multimers of the labelled oligonucleotide; smeary bands
in the middle of the gel may represent partial dissociation
of protein. In contrast, oligonucleotides lacking tails do
not compete. This was conﬁrmed by measuring binding at
a range of protein concentrations in the presence of an
1800-fold excess of untailed competitor (Figure 8B). The
competitor had no effect. Unsurprisingly, the morpholino
oligo (38) shows little evidence of binding to protein.
The importance of the tail for binding to SRSF1 was
conﬁrmed by direct immunoprecipitation of labelled
oligonucleotides after incubation at a concentration of
8nM with SRSF1 and immunoprecipitation buffer
A
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Figure 6. Effects of the site of annealing on the efﬁciency of TOES
oligonucleotides. (A) Diagram showing the positions of annealing of
the oligonucleotides to exon 7. Numbers are the designations of the
oligonucleotides. Oligonucleotides 1 and 8 anneal to exon 7 positions
2–16, 18 and 20 to 16–30, 21 and 22 to 18–32, 19 and 23 to 32–46, and
12, 25 and 15 to 7–21. Of these, oligonucleotides 8, 20, 22, 23 and 15
lack tails. (B) In vitro splicing assays with the oligoribonucleotides
shown above the lanes. The oligonucleotides labelled as bGt and bG
are complementary to b-globin exon 2; bG lacks a tail. The diagrams
on the right show the pre-mRNA and the two mRNA product
isoforms; the diagrams in grey show intermediates. As noted for
Figure 6, the presence of the RNA in which intron 2 has been
spliced is an indication of use of the inclusion pathway of splicing.
The bands above the pre-mRNA in lanes 19 and bGt, and above the
inclusion mRNA in bGt, result from persistent annealing of the oligo-
nucleotide in the denaturing gel. This is a feature of the oligonucleo-
tides in which the annealing portion contains LNA/20-O-methyl
analogues and 40% or more (G+C). (C) Qualitative RT–PCR
analysing splicing of endogenous SMN2 in ﬁbroblasts transfected
with some of the same oligonucleotides.
7202 Nucleic Acids Research, 2011,Vol.39, No. 16(Figure 8C). All oligonucleotides with a tail-bound
SRSF1, irrespective of the presence of an annealing
domain, except for oligonucleotide 21. The latter has a
pyrimidine-rich annealing domain that could form a sec-
ondary structure with the tail and thus prevent binding of
SRSF1 to the free oligonucleotide. We conclude that the
tail sequence is able to mediate SRSF1 binding.
Effects of tail chemistry on persistence of effects
Oligonucleotides containing an RNA tail are clearly ef-
fective reagents. However, the RNA domain might allow
rapid degradation of the oligonucleotide. To test whether
the chemistry of the tail or the annealing domain affects
the persistence of the response, oligonucleotides 1, 9 and
27 were transfected into ﬁbroblasts from a patient with
type II SMA as before and samples were removed at inter-
vals up to 10 days after transfection. Figure 9A shows that
in all three cases there was a signiﬁcant increase in the
levels of SMN protein until  7 days after transfection
(the relative increase in levels of SMN is shown under
each lane). Surprisingly, the shortest duration was seen
with 20-O-methyl modiﬁcation (oligonucleotide 27). If
transfection with oligonucleotide 1 is followed after 5
days by a second transfection and protein expression is
followed at intervals thereafter, it can be seen that SMN
protein levels remain high after all periods tested, i.e. even
up to 28 days after the second transfection (Figure 9B).
DISCUSSION
The purposes of this research were to optimize the design
of the bifunctional oligonucleotide used to rescue the
splicing of SMN2 exon 7 and to establish principles that
could be used to design oligonucleotides to rescue the
splicing of other exons. The efﬁciencies of the oligonucleo-
tides were assessed by three main assays, i.e. splicing
in vitro, measurements of the relative levels of the en-
dogenous isoforms expressed in transfected ﬁbroblasts
and measurements of the level of protein expressed in
these ﬁbroblasts. The assays of splicing in nuclear
extracts use transcripts containing exon 7 and ﬂanking
intron portions fused to ﬂanking globin sequences. The
endogenous sequence from exons 6–8 of SMN is about
7kb, which is impracticable for this purpose because
splicing in vitro becomes very inefﬁcient with transcripts
longer than around 1kb. However, the short substrate
contains most of the sequences identiﬁed to modulate
exon 7 inclusion and responds appropriately to mutations
in them, including sensitivity to exon nucleotide 6, and to
the TOES oligonucleotide (15). It had been anticipated
that differences in lipofectamine-mediated uptake, stabil-
ity within the cell or delivery to the nucleus would produce
substantial differences between the in vitro and cell-based
assays, but Figures 2 and 3 show that there was a
surprising level of agreement for most oligonucleotides.
Thus, splicing is the main determinant of efﬁciency. The
comparisons among oligonucleotides showed in addition
Figure 7. Rescue of splicing to SMN exon 7 by oligonucleotide 1 in vitro after mutation of GAA motifs. SMN2 is the normal substrate used for
in vitro assays; ESE-M is an otherwise identical transcript in which the GAA repeats in exon 7 had been mutated and nucleotide 6 had been
converted to the SMN1 nucleotide C. The pre-mRNA is the upper band in the triplet adjacent to the diagram of the pre-mRNA; the inclusion and
exclusion mRNA isoforms are also marked. The oligonucleotides shown were used at 100 and 250nM, as shown. Increased splicing to exon 7 is
associated with increased intensities of a higher band corresponding to mRNA in which the second but not the ﬁrst intron has been spliced, as noted
previously (15).
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determined by the number of GGA motifs in the tail, (ii)
GGA motifs were the most successful sequence tested and
could bind SRSF1, (iii) 20-O-methyl substitutions in the
tail did not reduce activity, (iv) modiﬁcations increasing
the stability of annealing reduced activity, (v) position is
an important determinant, (vi) annealing to an upstream
exon is effective and (vii) activity persists for at least 28
days after a second transfection and that RNA-containing
tails confer a more enduring response than 20-O-methyl
analogues.
The ﬁnding that the length of the tail, or the number of
GGA repeats, has such a strong inﬂuence on the efﬁciency
of a TOES oligonucleotide and has interesting mechanistic
implications. A systematic study of the effects of multiple
doublesex enhancers showed that their effects were
additive (36), from which it was inferred that the
limiting factor in their actions was the probability that a
bound activator protein would interact with constitutive
splicing components. Our results are consistent with those.
However, a recent analysis of responses to the transcrip-
tion factor NF-KB has provided a formal description of
other possible models (37). We envisage four possible
mechanisms for the effects of tail length, shown in
Figure 10. Model (i) suggests that there is a requirement
for a threshold number of proteins bound; models (ii) and
(iii) suggest that the multiple repeats of GGA increase
either the probability of occupancy by a protein or the
probability that a bound protein will interact subsequently
with other components, depending on which step is
limiting, whereas model (iv) suggests that bound
proteins can participate in several independent slow reac-
tions. Model (i) can be excluded by the graded response of
tails with different numbers of GGA motifs. Recently, we
determined the numbers of molecules of PTB bound to
polypyrimidine tracts by single molecule methods (38).
Based on our examination of possible arrangements of
the proteins on to the tracts, we suggested that proteins
containing multiple RNA binding domains with similar
speciﬁcities, connected by ﬂexible linkers, would have
higher apparent afﬁnities for sequences with repeated
target motifs as a result of the multiplicity of possible
binding sites and the multiplicity of arrangements
possible for the domains within each site; any inhibition
of the binding of multiple proteins might be attenuated if
the binding of each domain were weak and therefore
permitted shufﬂing of the domains (38). Such a mechan-
ism might be consistent with the effects of tail length ac-
cording to model (ii). However, the lack of detailed
structures of the RRM domains of SRSF1 with RNA
limits our ability to interpret the results. We are currently
using single molecule methods to investigate the
mechanism.
The substantial differences in performance between dif-
ferent tail sequences were surprising. The tails based on
GAC, GGACCG and GAA motifs (oligonucleotides 7, 17
and 14, respectively) were not very effective at all, even
though the GAC and GGACGG motifs in oligonucleo-
tides 7 and 17 were based on sequences identiﬁed as very
effective sites mediating activation by SRSF1, based on
functional selection (31,32), GAA motifs have been
reported to be optimal binding sites for SRSF1 in
SELEX experiments with recombinant protein (39), and
recent transcriptomic analyses by CLIP-SEQ conﬁrm that
the motif GAAGAR is enriched in transcripts bound
in vivo by SRSF1 (40). However, GAA and particularly
AGAA motifs are also associated with binding by the ac-
tivator Tra2b (41,42), which is known to bind such motifs
in the ESE of SMN2 exon 7 (34) and to stimulate the
recruitment of U2 snRNP to the 30-splice site (43). Thus,
if oligonucleotide 14 bound Tra2b it should stimulate
splicing. Preliminary results conﬁrm that the oligonucleo-
tide can bind puriﬁed Tra2b (N. Owen, unpublished data).
Our results may indicate that the level of Tra2b binding to
SMN2 exon 7 is not limiting, even though it has been
reported that transfection of plasmids expressing Tra2b
increases inclusion (34). The more important limitation
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Figure 8. Dependence of binding by SRSF1 on oligonucleotide tail
sequences. (A) Native gel electrophoresis showing displacement of
SRSF1 protein from oligonucleotide 27 by competing bifunctional
oligonucleotides. Reactions containing 50-end-labelled oligonucleotide
27 (six GGA motifs, fully 20O-methyl modiﬁed) were incubated with
excess recombinant SRSF1 protein and then mixed with an excess of
the oligonucleotide designated above the lanes. The displaced and
bound labelled oligonucleotides are marked. (B) Competition between
oligonucleotide 27 and untailed oligonucleotide 8 present at an
1800-fold higher concentration. (C) Immunoprecipitation of labelled
oligonucleotides with anti-SRSF1 antibody after incubation with re-
combinant SRSF1. Oligonucleotides are numbered above each lane.
The immunoprecipitates and input were analysed by gel electrophoresis
and exposed to a phosphor screen simultaneously.
7204 Nucleic Acids Research, 2011,Vol.39, No. 16may be the loss of an SRSF1 site in SMN2 exon 7 where
the SMN1 and SMN2 exons differ at nucleotide 6 (44,45).
Different tail sequences in TOES oligonucleotides have
been tested previously by expressing the oligonucleotide
from a snRNA promoter in transfected or infected cells.
Three sequences were expressed from a U6 snRNA
promoter (46). These were rich in (A+C), (G+C) and
GGA motifs, with the stated intentions of recruiting
SRSF1, SRSF2 and Tra2b, respectively. They all
worked, although they annealed (with a mismatch) to pos-
itions 6–26 in exon 7 and, in the absence of a control
untailed sequence in parallel experiments, it was not
clear to what extent the success was the result simply of
annealing. Several other sequences have been expressed
within a U7 minigene and compared with the original
tail domain of our oligonucleotide 1 (47). Two of the se-
quences were largely identical to the (A+C)-rich and
(G+C)-rich sequences tested by Baughan et al. (46), but
they were inactive when targeted to nucleotides 31–48. Of
the six tail sequences tested, the original sequence of oligo-
nucleotide 1 was by far the most active. We conclude that
GGA motifs confer the highest activity.
The position of annealing of a bifunctional oligonucleo-
tide was very important. There are two separate consider-
ations: the effects of annealing, which might obstruct
enhancer or silencer motifs or alter secondary structures,
Figure 9. Time course of SMN protein expression after transfection with oligonucleotides 1, 9 and 27. (A) SMA ﬁbroblasts were transfected and
samples taken at the intervals shown (d, days) for analysis by western blotting. (B) Persistence of elevated SMN protein levels after a second
transfection with oligonucleotide 1. SMA ﬁbroblasts were transfected and then re-transfected after 5 days. Samples were taken at the number of days
indicated after the second transfection and analysed by western blotting. Numbers under the lanes indicate the fold increases in the ratio of SMN to
tubulin protein.
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Figure 10. Possible models for the effects of the length of the tail on
the efﬁciency of splicing rescue. The diagram shows the bifunctional
oligonucleotide and protein SRSF1, which has two RRM domains
(ovals) and a RS-rich C-terminal region (shown unstructured). (i), a
threshold number of molecules of protein are required to bind before
activity is possible, possibly because proteins interact and binding is
cooperative; (ii), the greater number of repeated motifs in the longer
tails increases an otherwise extremely low afﬁnity or probability of
binding, (iii), the probability that a bound protein makes productive
contacts is low, but occupancy by multiple molecules increases this
probability, and (iv), bound proteins can make a number of different
contacts and the presence of multiple proteins allows a number of
concurrent interactions with other splicing components.
Nucleic Acids Research, 2011,Vol.39, No. 16 7205and limitations on the position of the tail within the exon.
The effects of annealing were distinguished by using
untailed control oligonucleotides. A number of proteins
are associated with the exon, including Tra2b (34),
hnRNP A1 (48,49), Sam68 (50), hnRNP G (51), hnRNP
Q (52) and SRSF9 (53). Where the binding sites of the
proteins have been mapped, they appear to be either
around nucleotide 6 or associated with the GAA motifs
around the enhancer between nucleotides 19 and 27. In
contrast, systematic surveys by saturating mutagenesis
(54) or oligonucleotide scanning (13) show a much more
complicated pattern. Oligonucleotides 18, 20, 21 and 22
inhibit inclusion; since they anneal across GAA motif nu-
cleotides 19–27, we infer that they inhibit essential binding
by Tra2b. Surprisingly, the successful TOES sequences
expressed from a U6 snRNA promoter annealed to this
region (46). Since mutating nucleotides 21–30 did not
prevent splicing being rescued by oligonucleotide 1, we
inferred that the tail can compensate for the absence of
Tra2b binding but that its position is critical.
Oligonucleotides 19 and 23 inhibited, even though they
do not obstruct any known binding site, but they overlap a
region close to the GAA motifs that has previously been
shown to be a target for inhibition by oligonucleotides
(nucleotides 29–34). The same region has been targeted
by a TOES sequence fused to U7 snRNA, but in this
case exon 7 inclusion was stimulated (47). The slight
positive effect of oligonucleotides 12 and 17 (annealing
to positions 7–21) is consistent with the results from oligo-
nucleotide scanning across the exon, which showed that an
oligonucleotide annealing to this site produced the highest
positive response among the oligonucleotides tested (13).
In this case, the failure of the tail to improve the outcome
is quite striking.
A possible explanation for the strong dependence of tail
activity on its location and position relative to the anneal-
ing domain was that the TOES oligonucleotides act on the
downstream 50-splice site, which we inferred from their
preferential stimulation of splicing of the downstream
intron. The tail may need to be positioned on the 50
rather than the 30-end of the oligonucleotide, i.e., on the
50 splice site side of the double-stranded region, so that
RNA ﬂexibility permits interactions. However, the oligo-
nucleotide cannot be too close to the 50-splice site, since
U1 snRNPs form interactions up to 18nt 50- of the
50-splice site (55) and the possibility of inhibition by prox-
imity has been shown by the mutual interference of
50-splice sites 25nt apart (23,56). With this in mind, we
designed the oligonucleotides complementary to the
upstream globin exon and to SMN2 exon 6, both of
which stimulated exon 7 inclusion efﬁciently, such that
they were, respectively, 51 and 66nt upstream of the
50-splice sites. Similarly, the site we selected for stimulating
inclusion of Ron exon 11 (57) was 55nt upstream of the
50-splice site. We infer that oligonucleotides annealing
further downstream than nucleotides 2–16 in SMN2
exon 7 might be too close to the 50-splice site.
The observation that TOES oligos targeted to upstream
exons is effective and raises interesting mechanistic ques-
tions. In the short substrate used for splicing in vitro,i ti s
likely that the formation of cross-intron interactions is
rate-limiting. Increasing the level of binding of U1
snRNPs at the 50-splice site of the upstream b-globin
exon might increase the rate of splicing in vitro,
although it is not obvious why it would increase the prob-
ability of splicing to the 30-splice site of SMN2 exon 7
rather than the distal b-globin exon. The effects on the
endogenous SMN2 gene in ﬁbroblasts are very striking.
Exon 6 is so far away (5.8kb) from exon 7 that inter-
actions across each exon would be expected to precede
cross-intron interactions and to determine the splicing
outcome (58). Based on this model, any increase in the
efﬁciency of binding of splicing factors to exon 6
mediated by the TOES oligo would be expected to
ensure exon 6 inclusion rather than exon 7 inclusion.
However, the results might be explained by a kinetic
model. If the TOES oligo annealed to exon 6 increased
the stability or rate of U1 snRNP binding to the 50-splice
site during transcription it might increase the chance that
the U1 was present on exon 6 at the moment when the
30-splice site of exon 7 was transcribed. This might result
in commitment to splicing between exons 6 and 7. Under
normal circumstances, if U1 binding were weaker, then
perhaps U1 snRNP would be more likely to bind exon 6
after both 30-splice sites (7 and 8) have been transcribed
and exon 7 would not have a kinetic advantage. It will be
important for applications in other genes to identify the
mechanisms involved.
The therapeutic value of oligonucleotides depends on
the availability of convenient methods for delivering
them to target tissues and their safety, and the
cost-effectiveness of any such therapy depends in part on
the frequency and dosage of administration. It has been
demonstrated in mice that oligonucleotides that anneal to
a silencer in SMN2 intron 7 can rescue necrosis in a mouse
model of SMA when injected into cerebral ventricles (59)
and that TOES oligonucleotides can rescue the phenotype
of SMA mice when expressed from a transgene (18).
Although ensuring the delivery of exogenous oligonucleo-
tides to the central nervous system will require major
advances in the methods of delivery, the success of oligo-
nucleotides stimulating skipping of a dystrophin exon in
clinical trials with systemic administration bodes well for
the future. The oligonucleotides targeted to a silencer in
intron 7 were shown to persist for at least 2 months in
neuronal tissue and to produce an effect for at least half a
year (59). These oligonucleotides were fully modiﬁed. We
were surprised to ﬁnd that the effects of a second trans-
fection of a TOES oligonucleotide persisted for at least a
month in ﬁbroblasts, not least because in oligonucleotide 1
the majority of the tail sequence comprises of unmodiﬁed
RNA. A likely explanation of this persistence is that the
tail domain of the oligonucleotide becomes incorporated
into discrete and well-deﬁned RNP complexes, as we have
observed in nuclear extracts (R. Dickinson, unpublished
data).
We conclude that the very high levels of recovery of
SMN2 exon 7 inclusion and SMN protein expression
associated with oligonucleotide 1 and the persistence of
its effects suggest that it is an appropriate candidate for
further investigation as a potential therapeutic reagent in
SMA. The levels of enhancement of SMN protein
7206 Nucleic Acids Research, 2011,Vol.39, No. 16expression exceed any other quantitative data yet pub-
lished. We suggest the following design principles for
TOES oligonucleotides: (i) the tail should comprise
GGA motifs, (ii) as many as possible should be
included, (iii) the tail should be unmodiﬁed, apart from
a cap, (iv) annealing should not be too stable, (v) the
oligonucleotide should anneal more than 40nt upstream
of a 50-splice site and (vi) splicing of the target exon should
be limited by its 50-splice site strength. It is likely that even
more effective reagents could be made if more was known
about the mechanisms by which enhancers and the SR
proteins bound to them act to stimulate splicing.
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